The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...
Verywell Health on MSN8h
17 Important Resources for Someone Who Has Metastatic Breast CancerIf you have been diagnosed with metastatic breast cancer, resources like support groups, counseling, financial assistance, and online communities can help.
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.
DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or ...
The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...
The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...
Routine screening for patient-reported outcomes may improve access to supportive care services among long-term metastatic breast cancer survivors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback